[go: up one dir, main page]

EP1185528A4 - Inhibitors of il-12 production - Google Patents

Inhibitors of il-12 production

Info

Publication number
EP1185528A4
EP1185528A4 EP00941360A EP00941360A EP1185528A4 EP 1185528 A4 EP1185528 A4 EP 1185528A4 EP 00941360 A EP00941360 A EP 00941360A EP 00941360 A EP00941360 A EP 00941360A EP 1185528 A4 EP1185528 A4 EP 1185528A4
Authority
EP
European Patent Office
Prior art keywords
compound
heteroaryl
aryl
alkyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00941360A
Other languages
German (de)
French (fr)
Other versions
EP1185528A1 (en
Inventor
Mitsunori Ono
Yumiko Wada
Beatrice Brunkhorst
Tadeusz Warchol
Wojciech Wrona
Dan Zhou
Nha Huu Vo
Stephen Gillies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBR Pharmaceuticals Inc
Original Assignee
SBR Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBR Pharmaceuticals Inc filed Critical SBR Pharmaceuticals Inc
Publication of EP1185528A1 publication Critical patent/EP1185528A1/en
Publication of EP1185528A4 publication Critical patent/EP1185528A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Cytokines such as interleukin-12 (IL-12) mediate the acute phase response to inflammatory stimuli, enhance the microbicidal functions of macrophages and other cells, and promote specific lymphocyte responses. See, e.g., I Q Fearon and Locksley, Science 272:50 (1996).
  • IL-12 interleukin-12
  • L 1 is -A 1 -B 1 -, in which -A 1 - is -(CH(R a )) -, -0-, -S-, or -N(R b )- and -B 1 - is -(CH(R C )) - or a bond.
  • Each of R a and R c is hydrogen, 5 alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl , formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, cycloalkyl, heterocycloalkyl, aryl, 0 aralkyl, heteroaryl, or heteroaralkyl.
  • R b is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl. Each of m and n, independently, is 1-8.
  • W is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which « being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or 0 alkylcarbonyloxy.
  • R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 1S , R 16 , R 17 , R 18 , R 19 , R 2 °, R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , and R 27 independently, is hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
  • Y is -R'-L'-R" wherein R' is a bond, or cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which optionally being substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, or alkoxycarbonylimino.
  • L' is a bond, -0-, -S-, -N(R 28 )-, -N(R 29 )-CO-, -CO-N(R 30 )-, -CO-0-, or -O- CO- .
  • R 28 , R 29 , and R 30 independently, is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
  • R" is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy.
  • Z is morpholinyl which is optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy.
  • Another aspect of this invention relates to a method of inhibiting IL-12 production, which includes administering to a patient in need thereof an effective amount of a compound of formula (I) , supra - X is triazinyl.
  • L 1 is -A ⁇ -B 1 - , in which -A 1 - is -(CH(R a )) m -, -0-, -S-, or -N(R b )- and -B 1 - is -(CH(R c )) n - or a bond.
  • Each of R a and R c is hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl.
  • R b is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl. Each of m and n, independently, is 1-8.
  • W is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl, each of which being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy.
  • L 2 is -A 2 -B 2
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R" , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , and R 27 independently, is hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
  • Y is -R'-L'-R" wherein R' is a bond, or cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, or alkoxycarbonylimino.
  • L' is a bond, -0-, -S-, -N(R 28 )-, -N(R 29 )-C0-, -CO-N(R 30 ) -, -CO-0-, or -O-CO- .
  • R 28 , R 29 , and R 30 independently, is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
  • R" is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which optionally being substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy.
  • Z is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy.
  • a pharmaceutically acceptable salt of a compound of formula (I) is also within the scope of this invention.
  • a salt can be formed between a negatively charged substituent such as carboxylate and a positively charged counte ⁇ on such as an alkali metal ion (e.g., a sodium ion or a potassium ion) ; an alkaline earth metal ion (e.g., a magnesium ion or a calcium ion); an ammonium ion (NH + ) ; or an organic ammonium group such as tetramethylammonium ion or dnsopropylethyl -ammonium ion.
  • a negatively charged substituent such as carboxylate
  • a positively charged counte ⁇ on such as an alkali metal ion (e.g., a sodium ion or a potassium ion) ; an alkaline earth metal ion (e.g., a magnesium ion or a calcium ion); an am
  • an ammo substituent can form a salt with a negatively charged counterion.
  • Suitable counterions include, but are not limited to, chloride, hydrochlo ⁇ de, bromide, iodide, sulfate, nitrate, phosphate, or acetate.
  • alkyl is a straight or branched hydrocarbon chain containing 1 to 12 carbon atoms.
  • alkyl examples include, but are not limited to, methyl, ethyl, propyl , isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, n-pentyl, 2-methylhexyl , 3-ethyloctyl , a n 4-ethyldecyl .
  • alkenyl refers to a straight or branched hydrocarbon chain containing 2 to 12 carbon atoms and one or more (e.g., 1-6) double bonds.
  • alkynyl also refers to such a hydrocarbon chain, except that the chain contains one or more triple bonds instead of double bonds.
  • Some examples of alkenyl and alkynyl are allyl, 2-butenyl, 2-pentenyl, 2-hexenyl, 2-butynyl, 2-pentynyl and 2-hexynyl.
  • cycloalkyl is meant a cyclic alkyl group containing 3 to 8 carbon atoms. Some examples of cycloalkyl are cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl , and norbornyl .
  • Heterocycloalkyl is a cycloalkyl group containing 1-3 heteroatoms such as nitrogen, oxygen, or sulfur. Examples of heterocycloalkyl include piperidinyl, piperazinyl, tetrahydropyranyl , tetrahydrofuryl , and morpholinyl.
  • Cycloalkenyl is a cycloalkyl group containing one or more (e.g., 1-3) double bonds. Examples of such a group include cyclopentenyl , 1, 4-cyclohexadienyl , cycloheptenyl , and cyclooctenyl groups.
  • heterocycloalkenyl is a heterocycloalkyl group containing one or more double bonds.
  • aryl is an aromatic group containing 6-12 ring atoms and can contain fused rings, which may be saturated, unsaturated, or aromatic. Examples of an aryl group include phenyl, naphthyl, biphenyl, phenanthryl , and anthracyl .
  • Heteroaryl is aryl containing 1-3 heteroatoms such as nitrogen, oxygen, or sulfur and can contain fused rings .
  • Some examples of heteroaryl are pyridyl, furanyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl , benzofuranyl , and benzthiazolyl .
  • a cyclic moiety can be cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl.
  • a tricyclic moiety is a fused ring formed from three of the just-mentioned moieties.
  • An example of a tricyclic moiety is dibenzocycloheptenyl .
  • Heteroatoms such as nitrogen, oxygen, and sulfur can be included in the cyclic moiety.
  • An amino group can be unsubstituted, mono- substituted, or di-substituted. It can be substituted with groups such as alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
  • Halo refers to fluoro, chloro, bromo, or iodo.
  • a compound of formula (I) can be prepared in a stepwise manner by using cyanuric chloride as a starting material.
  • Cyanuric chloride is commercially available.
  • the three chloro groups of cyanuric chloride can be successively displaced by various nucleophilic substituents. The order of displacement is not of particular importance.
  • a chloro group of cyanuric chloride can be substituted with a nucleophile W-B 1 - ⁇ 1 -U wherein A 1 is -0-,
  • R a and m have been defined above
  • organometallic compound of group IA or IIA metal e.g., a Grignard reagent.
  • the organometallic compound acts as a nucleophile and reacts with a compound with a good leaving group, e.g., an alkyl halide, to form a carbon- carbon linkage.
  • a chloro group of cyanuric chloride can also be displaced by a nucleophile ZH (Z has been defined above) , e.g., morpholine, to form a morpholinyl triazine compound as shown in the following reaction (see, e.g., Step (2) of Example 1 for details) :
  • a chloro group of cyanuric chloride can undergo yet another displacement reaction with a nucleophile H-A 2 -B 2 -Y wherein A 2 is an amine and B 2 is a bond to form an amino linkage between the triazine ring and the nucleophile.
  • Some examples of such an amine include 3-aminocarbazole, 6-aminobenzofuran, and 4- (3-methylphenyl) aniline . See, e.g., Step (3) of Example 5.
  • Step (3) of Example 5 See, e.g., Step (3) of Example 5.
  • the chloro group can be first displaced by hydrazine, and the primary amine of the coupled hydrazine moiety can then react with an aldehyde to form an imine linkage :
  • a compound of formula (I) wherein the linkage -A-B 2 - is a carbon-carbon linkage can be formed, e.g., via an organometallic intermediate described above and further reacting such an intermediate with a nucleophile.
  • linkages can be prepared by similar nucleophilic reactions. Sensitive moieties on both the triazinyl intermediates and the nucleophiles can be protected prior to coupling. For suitable protecting groups, see, e.g., Greene, T. . , Protective Groups in Organic Synthesis, John Wiley & Sons, Inc., New York (1981) .
  • a compound of formula (I) prepared by the methods shown above can be purified by flash column chromatography, preparative high performance liquid chromatography, or crystallization.
  • a pharmaceutical composition containing an effective amount of one or more compounds of this invention for inhibiting IL-12 production or treating an IL-12 mediated disorders is also within the scope of this invention.
  • Some examples of IL-12 mediated disorders include sepsis and autoimmune disorders, e.g., rheumatoid arthritis, Crohn's disease, psorasis, and multiple sclerosis.
  • the use of a compound of this invention or a salt thereof for the manufacture of a medicament for inhibiting IL-12 production or treating the above-mentioned IL-12-mediated disorders is also within the scope of this invention.
  • Still another aspect of this invention is a method of treating an IL-12 -mediated disorder, e.g., sepsis, by administering to a patient a pharmaceutical composition containing an effective amount of a compound of this invention or a salt thereof.
  • An effective amount is defined as the amount which is required to confer a therapeutic effect on the treated patient, and is typically determined based on age, surface area, weight, and condition of the patient. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al . , Cancer Chemother. Rep. 1966, 50, 219. Body surface area may be approximately determined from height and weight of the patient.
  • an effective amount of a compound of this invention can range from about 0.1 mg/kg to about 100 mg/kg. Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments such as the use of other anti- inflammatory agents.
  • the pharmaceutical composition may be administered via the parenteral route, including orally, topically, subcutaneously, intraperitoneally, intramuscularly, and intravenously.
  • parenteral dosage forms include aqueous solutions, isotonic saline or 5% glucose of the active agent, or other well-known pharmaceutically acceptable excipient.
  • Solubilizing agents such as cyclodextrins, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the therapeutic compounds .
  • compound of this invention can be formulated into dosage forms for other routes of administration utilizing conventional methods. For example, it can be formulated in a capsule, a gel seal, or a tablet for oral administration.
  • Capsules may contain any standard pharmaceutically acceptable materials such as gelatin or cellulose. Tablets may be formulated in accordance with conventional procedures by compressing mixtures of a compound of this invention with a solid carrier and a lubricant. Examples of solid carriers include starch and sugar bentonite. A compound of this invention can also be administered in a form of a hard shell tablet or a capsule containing a binder, e.g., lactose or mannitol, a conventional filler, and a tableting agent.
  • a binder e.g., lactose or mannitol
  • the biological activities of a compound of this invention can be evaluated by a number of cell -based assays.
  • One of such assays can be conducted using mononuclear cells from human peripheral blood (PBMC) .
  • Human Interferon gamma (IFN- ⁇ ) and lipopolysaccharide are added to the cell-containing solutions to induce IL-12 production.
  • a solution containing a compound of this invention is added to each well.
  • the level of inhibition of IL-12 production can be measured by determining the amount of P70 (i.e., IL-12) by using a sandwich ELISA assay - 1 with anti-human IL-12 antibodies. ICso of each test compound can then be determined and potent compounds are selected for further testing.
  • the selected compounds can be further assayed in parallel on two types of cells, PBMC and human leukemia mononuclear cell line (THP-1) , for verification. More specifically, each test compound is added to a well of stimulated PBMC or THF-1 cells. PBMC are stimulated by a combination of IFN- ⁇ and LPS, and THP-1 cells are stimulated by a combination of IFN- ⁇ and pansorbin. The amount of P70 present in each well is then measured using a sandwich ELISA with anti -human IL-12 antibodies and IC is determined for each test compound.
  • THP-1 human leukemia mononuclear cell line
  • the cytotoxity of the test compounds of this invention can be determined by using a bioreductive assay. Specifically, PBMC and THP-1 cells are incubated with the test compounds. Viability are evaluated by the ability of mitochondrial dehydrogenases of the incubated cells to reduce 3- (4, 5-dimethylthiazole-2-yl) -5- (3- carboxymethoxy-phenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS) in the presence of phenazine methosulfate (PMS) .
  • PBMC and THP-1 cells are incubated with the test compounds. Viability are evaluated by the ability of mitochondrial dehydrogenases of the incubated cells to reduce 3- (4, 5-dimethylthiazole-2-yl) -5- (3- carboxymethoxy-phenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS) in the presence of phenazine
  • Compounds of this invention can also be evaluated by animal studies.
  • One of such studies involves the ability of a test compound to inhibit septic shock. Animals are injected with LPS to induce septic shock. Mortality rate of the induced animals is monitored after administering to the animals a test compound and compared with that of a control experiment in which the induced animals are not treated.
  • the following specific examples, which describe syntheses and biological testings of compounds of this invention, are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
  • X H nuclear magnetic resonance spectra were recorded on a Varian Mercury 300 MHz spectrometer.
  • ES mass spectra were recorded on a Finnigan Navigator mass spectrometer.
  • Step (1)
  • Cyanuric chloride (18.7 g, 0.10 mol) was added to a solution of methylene chloride (100 mL) . Phenethyl alcohol (12.2 g, 0.10 mol) and N, N-dimethyacetamide (26.1 g, 0.30 mol) were then added after cyanuric chloride was dissolved. The reaction mixture was refluxed for 10 hours, cooled to room temperature, diluted with methylene chloride (100 ml), washed with water (100 ml, 3 times), dried over MgSO , and then filtered.
  • Step (2) Morpholine (8.70 g, 0.10 mol) and diisopropylethylamine (12.9 g, 0.10 mol) were dissolved in 20 ml methylene chloride and added dropwise into the filtrate from step (1) at 0°C. The reaction was monitored by TLC (EtOAc :Hexane, 1:4). After the product was formed, the reaction mixture was washed with IN HCI (50 ml, 3 times), saturated NaHCO. (50 ml), brine (50 ml), then dried over MgSO . The solvent was removed under reduced pressure. The crude residue was recrystallized from acetone/water solution to give 20.5 g of the desired triazine monochloride intermediate. Step (3)
  • the triazine monochloride intermediate (20.0 g, j 0 0.062 mol) was dissolved in 100 ml ethanol and added dropwise to a solution of hydrazine monohydrate (25.0 g, 0.62 mol) in ethanol (50 ml) . The mixture was stirred at room temperature for 30 minutes before 20 ml water was added. Excess ethanol was then removed under reduced j pressure and the desired triazinyl hydrazine precipitated out which was collected by filtration and washed with water.
  • Triazinyl hydrazine (316 mg, 1.0 mmol) and indole 3- carboxylaldehyde (145 mg, 1.0 mmol) were added to 5 ml 0 methanol and warmed to form a homogeneous solution. Two drops of glacial acetic acid was then added. After the reaction mixture was allowed to stand at room temperature for 10 hours, the product precipitated which was then filtered, washed with methanol, and dried under reduced 5 pressure to yield compound 1 (395 mg, 89%) . ⁇ NMR
  • Step (3) Preparation of compound 2 Steps (1) and (2) of the preparation were prepared in an identical manner described in Example 1 except that 2- (4-methoxyphenyl) ethanol was used instead of phenethyl alcohol . 5 Step (3) :
  • Triazinyl monochloride (330 mg, 1.0 mmol) was added to 10 ml of 1,4 -dioxane, followed by the addition of 3- aminocarbazole (182 mg, 1.0 mmol) and diisopropylethylamine (129 mg, 1.0 mmol) .
  • 3- aminocarbazole 182 mg, 1.0 mmol
  • diisopropylethylamine 129 mg, 1.0 mmol
  • the triazine dichloride intermediate (3.0 g, 10 5 mmol) was dissolved m acetone (30 ml) After the acetone solution was cooled to 0°C, a 10 ml aqueous solution of sodium bicarbonate (0.842 g, 10 mmol) was added to the acetone solution with stirring. Morpholine (0.87 ml, 10 mmol) was added dropwise to mixture and j 0 white precipitate was formed within 10 minutes The precipitate was filtered and washed with water (3 times) and dried under vacuum to yield the desired triazine monochloride intermediate (4.0 g, >98%) as a white solid. Step (3) : j 5 The triazine monochloride intermediate (3.5 g,
  • Step (1)
  • Cyanuric chloride (13.66 g, 74 mmol) was dissolved j 0 in methylene chloride (100 ml) at -78°C, followed by the addition of diisopropylethylamine (12.9 ml, 74 mmol).
  • the reaction mixture was stirred for 5 minutes.
  • Step (2)
  • Step (3)
  • Steps (1) and (2) of the preparation were prepared in an identical manner described in Example 3 except that (3 , 4-dimethoxyphenyl) ethanol was used instead of 4- hydroxy-3-methoxyphenethyl alcohol .
  • Step (3)
  • the triazine monochloride intermediate (760 mg, 2.0 mmol) was dissolved in 10 ml DMF.
  • 4-(N-(2- methoxyphenyl) amino) aniline (429 mg, 2.0 mmol) and DIEA (387 mg, 3.0 mmol) were then added to the DMF solution.
  • the reaction mixture was allowed to react at 100°C for 15 hours. After cooling to room temperature, the mixture was diluted with ethyl acetate (50 ml), washed with HO (3 X 25 ml) , brine (25 ml) , dried over MgSO , filtered, and concentrated under reduced pressure.
  • Steps (1) and (2) of the preparation were identical to the corresponding steps described in Example 5.
  • Step (3) Steps (1) and (2) of the preparation were identical to the corresponding steps described in Example 5.
  • PBMC peripheral blood
  • fetal calf serum (10%)
  • penicillin penicillin
  • streptomycin L-glutamate
  • Human Interferon gamma IFN- ⁇ was added to the solution containing the cells at the concentration of 60 units/ml (obtained from Boehringer Mannheim; catalog no. 1040596) .
  • Example 29 The specificity of the nine selected compound (see Example 29) was tested on PBMC and human leukemia mononuclear cell line THP-1 in parallel to verify results .
  • PBMC peripheral blood mononuclear cells
  • IFN- ⁇ 200 U/mL
  • LPS 1 ⁇ g/mL
  • THP-1 cells were plated in wells of a 96-well plate at a concentration of 800,000 cells per well (100 ⁇ l). Human IFN- ⁇ was added at 2000 U/ml . The plate was incubated overnight under a 7% CO atmosphere at 37°C.
  • Each selected test compound (in 4X RPMI solution) was then added to a well of the 96 well plate with a final concentration of 1 ⁇ g/ml, which was then followed by the addition of Staph Aureus Cowan I (SAC or Pansorbin; obtained from Calbiochem; Lot # B15921) with a final concentration of 0.05%.
  • the plate was then gently vortexed and incubated for 16 hours under a 7% CO 2 atmosphere at 37°C.
  • Supernatant was harvested and was assayed for the amount of P70 present by using a sandwich ELISA with anti -human IL-12 antibodies (obtained from R&D systems; catalog no. mAb 611 and catalog no. BAF219) .
  • the nine selected test compounds all showed similar biological activities towards both PBMC and THP-1 cells.
  • THP-1 cell line The two most potent compounds showed a 10-fold increase in inhibiting IL-12 production over a known anti-inflammatory compound, dexamethazone .
  • the nine selected compounds were also assayed for cytotoxicity using a Cell Titer 96 Aqueous Non-radioactive kit (obtained from Promega, order 5 no. G5421) .
  • 3- (4, 5-Dimethylthiazole-2-yl) -5- (3- j 0 carboxymethoxy-phenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS) was then added.
  • the nine test compounds all showed similar trend in cytotoxity toward the two cell lines.
  • the PBMC cell line one compound showed a CC of under 1 ⁇ M; five compounds showed a CC of between 2-10 ⁇ M; and three 5 compounds showed a CC so of 20 ⁇ M or above.
  • the THP-1 cell line one compound showed a CC of about 2 ⁇ M; five compounds showed a CC of about 20 ⁇ M; and three compounds showed a CC of above 20 ⁇ M.
  • four compounds 0 showed a lower cytotoxity toward the PBMC cell line, and three compounds showed a lower cytotoxity toward the THP- 1 cell line.
  • mice Three compounds of this invention were tested an animal study using Balb/c mice.
  • the mice were divided into groups of five. Septic shock was induced m each of them by single tradermal injection of LPS (1 ⁇ g/mL) m the foot pad. After 24 hours, a group of mice received (1) no treatment; another group received (2) vehicle only (10% DMSO and 18% Cremophor RH40) ; or three groups received (3) test compounds. More specifically, each group received a different test compound at a dosage of 10-20 mg/kg. The mice were dosed daily for three days and the mortality rate m each group was then recorded. The mice all died m the groups that received no treatment or vehicle only. Among the groups that received test compounds, two had a survival rate of 60% and 80%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to a compound of formula (I) which can inhibit the production of IL-12. Also disclosed is a method of inhibiting IL-12 production by administering to a patient in need thereof an effective amount of a compound of formula (I).

Description

INHIBITORS OF IL-12 PRODUCTION
5 Background of the Invention
Cytokines such as interleukin-12 (IL-12) mediate the acute phase response to inflammatory stimuli, enhance the microbicidal functions of macrophages and other cells, and promote specific lymphocyte responses. See, e.g., IQ Fearon and Locksley, Science 272:50 (1996).
Recently, ±n vivo studies revealed that inhibition of IL-12 production has therapeutic effects against inflammatory disorders such as sepsis (Zisman et al . , Eur. J. Immunol. 27:2994 (1997)), collagen induced j5 arthritis (Malfait et al . , Clin. Exp . Immunol. 111:377
(1998)), established colitis (U.S. Patent No. 5,853,697), experimental autoimmune encephalomyelitis (Leonard et al., J. Exp. Med. 181:381 (1995)), experimental autoimmune uveoretinitis (Yokoi et al . , Eur. J. Immunol.
20 27:641 (1997)), psoriasis (Turka et al . , Mol. Med. 1:690 (1995) ) , and cyclophosphamide induced diabetes (Rothe et al., Diabetologia 40:641 (1997)).
Production of IL-12 can be inhibited by anti-IL-12 antibodies. However, long term treatments of chronic
25 diseases with such antibodies are expensive. Also, antibodies can be unstable after administration. Thus, there exists a need for use of small non-protein compounds instead of anti-IL-12 antibodies to inhibrut the production of IL-12.
30 Summary of the Invention An aspect of this invention relates to a compound of formula (I) :
(I)
X is triazinyl . L1 is -A1-B1-, in which -A1- is -(CH(Ra)) -, -0-, -S-, or -N(Rb)- and -B1- is -(CH(RC)) - or a bond. Each of Ra and Rc, independently, is hydrogen, 5 alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl , formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, cycloalkyl, heterocycloalkyl, aryl, 0 aralkyl, heteroaryl, or heteroaralkyl. Rb is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl. Each of m and n, independently, is 1-8. W is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which « being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or 0 alkylcarbonyloxy. L2 is -A2-B2-, in which A2 is a bond, -N(R1)-, or - (-C(R2) (R3) -) -, and B2 is a bond, -N=C(R4)-,
-C(R5)_=N-, -C(R6)=C(R7) -, -N(R8)=N(R9) -, -N (R10) -C (R11) (R12) - , -0-C(R") (R14) -, -CO-C(R15) (R16) -, -C0-N(R17)-, -N(R18)-C0-, -CO-, -CO-O-, -C0-S-, -S-C(R19) (R20) -, -CS-C (R21) (R22) - , -CS-
N(R23)-, -N(R24)-CS-, -CS-, -SD2-, provided that -A2-B2- cannot be a bond. -A2-B2- together is -0-, -S-, - (-0-(CH2)q-0-)r-, - (-N(R2s)-(CH2)s-CO-)t-, or - (-N(R26) - (CH2)u-N(R27) -)v-. Each of R1, R2, R3, R4, R5, R6,
R7, R8, R9, R10, R11, R12, R13, R14, R1S, R16, R17, R18, R19, R2°, R21, R22, R23, R24, R25, R26, and R27, independently, is hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl. Each of p, q, r, s, t, u, and v, independently, is 1, 2, or 3. Y is -R'-L'-R" wherein R' is a bond, or cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which optionally being substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, or alkoxycarbonylimino. L' is a bond, -0-, -S-, -N(R28)-, -N(R29)-CO-, -CO-N(R30)-, -CO-0-, or -O- CO- . Each of R28, R29, and R30, independently, is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl. R" is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy. Z is morpholinyl which is optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy. Another aspect of this invention relates to a method of inhibiting IL-12 production, which includes administering to a patient in need thereof an effective amount of a compound of formula (I) , supra - X is triazinyl. L1 is -A^-B1- , in which -A1- is -(CH(Ra))m-, -0-, -S-, or -N(Rb)- and -B1- is -(CH(Rc))n- or a bond.
Each of Ra and Rc, independently, is hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl. Rb is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl. Each of m and n, independently, is 1-8. W is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl, each of which being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy. L2 is -A2-B2-, in which A2 is a bond,
-N(R!)-, or -(-C(R2) (R3)-) -, and B2 is a bond, -N=C(R4)-, -C(R5)=N-, -C(R6)=C(R7) -, -N(R8)=N(R9) -, -N (R10) -C (R11) (R12) -0-C(R13) (R14) -, -CO-C(R15) (R16) -, -CO-N(R17)-, -N(R18)-CO-, -CO-, -CO-0-, -CO-S-, -S-C(R19) (R20) -, -CS-C (R21) (R22) - , -CS-N(R23)-, -N(R24) -CS-, -CS-, -S02-, provided that -A2-B2- cannot be a bond. -A2-B2- together is -0-, -S-,
- (-0- (CH2)q-0-)r-, - (-N(R25)- (CH2)s-CO-) t-, or
- (-N(R26) - (CH2)u-N(R27) -) v- . Each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R" , R15, R16 , R17, R18 , R19 , R20, R21, R22, R23, R24, R25, R26, and R27, independently, is hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl. Each of p, q, r, s, t, u, and v, independently, is 1, 2, or 3. Y is -R'-L'-R" wherein R' is a bond, or cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, or alkoxycarbonylimino. L' is a bond, -0-, -S-, -N(R28)-, -N(R29)-C0-, -CO-N(R30) -, -CO-0-, or -O-CO- . Each of R28, R29, and R30, independently, is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl. R" is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which optionally being substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy. Z is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy. Set forth below are exemplary of compounds of this invention:
H
A pharmaceutically acceptable salt of a compound of formula (I) is also within the scope of this invention. For example, a salt can be formed between a negatively charged substituent such as carboxylate and a positively charged counteπon such as an alkali metal ion (e.g., a sodium ion or a potassium ion) ; an alkaline earth metal ion (e.g., a magnesium ion or a calcium ion); an ammonium ion (NH +) ; or an organic ammonium group such as tetramethylammonium ion or dnsopropylethyl -ammonium ion. As another example, if an ammo substituent can form a salt with a negatively charged counterion. Suitable counterions include, but are not limited to, chloride, hydrochloπde, bromide, iodide, sulfate, nitrate, phosphate, or acetate. As used herein, alkyl is a straight or branched hydrocarbon chain containing 1 to 12 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, propyl , isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, n-pentyl, 2-methylhexyl , 3-ethyloctyl , an 4-ethyldecyl .
The term "alkenyl" refers to a straight or branched hydrocarbon chain containing 2 to 12 carbon atoms and one or more (e.g., 1-6) double bonds. The term "alkynyl" also refers to such a hydrocarbon chain, except that the chain contains one or more triple bonds instead of double bonds. Some examples of alkenyl and alkynyl are allyl, 2-butenyl, 2-pentenyl, 2-hexenyl, 2-butynyl, 2-pentynyl and 2-hexynyl.
By cycloalkyl is meant a cyclic alkyl group containing 3 to 8 carbon atoms. Some examples of cycloalkyl are cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl , and norbornyl . Heterocycloalkyl is a cycloalkyl group containing 1-3 heteroatoms such as nitrogen, oxygen, or sulfur. Examples of heterocycloalkyl include piperidinyl, piperazinyl, tetrahydropyranyl , tetrahydrofuryl , and morpholinyl. Cycloalkenyl is a cycloalkyl group containing one or more (e.g., 1-3) double bonds. Examples of such a group include cyclopentenyl , 1, 4-cyclohexadienyl , cycloheptenyl , and cyclooctenyl groups. By the same token, heterocycloalkenyl is a heterocycloalkyl group containing one or more double bonds. As used herein, aryl is an aromatic group containing 6-12 ring atoms and can contain fused rings, which may be saturated, unsaturated, or aromatic. Examples of an aryl group include phenyl, naphthyl, biphenyl, phenanthryl , and anthracyl . Heteroaryl is aryl containing 1-3 heteroatoms such as nitrogen, oxygen, or sulfur and can contain fused rings . Some examples of heteroaryl are pyridyl, furanyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl , benzofuranyl , and benzthiazolyl .
A cyclic moiety can be cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl. A tricyclic moiety is a fused ring formed from three of the just-mentioned moieties. An example of a tricyclic moiety is dibenzocycloheptenyl . Heteroatoms such as nitrogen, oxygen, and sulfur can be included in the cyclic moiety.
An amino group can be unsubstituted, mono- substituted, or di-substituted. It can be substituted with groups such as alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl. Halo refers to fluoro, chloro, bromo, or iodo.
Compounds of this invention show an unexpected high level of potency in inhibiting the production of IL-12. Other features or advantages of the present invention will be apparent from the following detailed description of several embodiments, and also from the appending claims.
Detailed Description of the Invention A compound of formula (I) can be prepared in a stepwise manner by using cyanuric chloride as a starting material. Cyanuric chloride is commercially available. The three chloro groups of cyanuric chloride can be successively displaced by various nucleophilic substituents. The order of displacement is not of particular importance. For example, a chloro group of cyanuric chloride can be substituted with a nucleophile W-B1-Α1-U wherein A1 is -0-,
-S-, or -N(Rb)-, and W and B1 have been defined above, thus forming an ether linkage. Below is an example of a displacement reaction in which the nucleophile is phenethyl alcohol (i.e., A1 is -0-, B1 is -CH2~CH2-, and W is phenyl) :
Cl
A compound of formula (I) wherein A1 is -(CH(Ra))m-
(Ra and m have been defined above) can be prepared by first converting cyanuric chloride to an organometallic compound of group IA or IIA metal, e.g., a Grignard reagent. The organometallic compound acts as a nucleophile and reacts with a compound with a good leaving group, e.g., an alkyl halide, to form a carbon- carbon linkage.
A chloro group of cyanuric chloride can also be displaced by a nucleophile ZH (Z has been defined above) , e.g., morpholine, to form a morpholinyl triazine compound as shown in the following reaction (see, e.g., Step (2) of Example 1 for details) :
A chloro group of cyanuric chloride can undergo yet another displacement reaction with a nucleophile H-A2-B2-Y wherein A2 is an amine and B2 is a bond to form an amino linkage between the triazine ring and the nucleophile. Some examples of such an amine include 3-aminocarbazole, 6-aminobenzofuran, and 4- (3-methylphenyl) aniline . See, e.g., Step (3) of Example 5. On the other hand, as shown in the following reaction, if the desired linkage -A2-B2- is
-NH-N=CH- , the chloro group can be first displaced by hydrazine, and the primary amine of the coupled hydrazine moiety can then react with an aldehyde to form an imine linkage :
EtOH, HOAc, reflux
A compound of formula (I) wherein the linkage -A-B2- is a carbon-carbon linkage can be formed, e.g., via an organometallic intermediate described above and further reacting such an intermediate with a nucleophile.
Other types of linkages can be prepared by similar nucleophilic reactions. Sensitive moieties on both the triazinyl intermediates and the nucleophiles can be protected prior to coupling. For suitable protecting groups, see, e.g., Greene, T. . , Protective Groups in Organic Synthesis, John Wiley & Sons, Inc., New York (1981) .
A compound of formula (I) prepared by the methods shown above can be purified by flash column chromatography, preparative high performance liquid chromatography, or crystallization.
A pharmaceutical composition containing an effective amount of one or more compounds of this invention for inhibiting IL-12 production or treating an IL-12 mediated disorders is also within the scope of this invention. Some examples of IL-12 mediated disorders include sepsis and autoimmune disorders, e.g., rheumatoid arthritis, Crohn's disease, psorasis, and multiple sclerosis. The use of a compound of this invention or a salt thereof for the manufacture of a medicament for inhibiting IL-12 production or treating the above-mentioned IL-12-mediated disorders is also within the scope of this invention. Still another aspect of this invention is a method of treating an IL-12 -mediated disorder, e.g., sepsis, by administering to a patient a pharmaceutical composition containing an effective amount of a compound of this invention or a salt thereof. An effective amount is defined as the amount which is required to confer a therapeutic effect on the treated patient, and is typically determined based on age, surface area, weight, and condition of the patient. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al . , Cancer Chemother. Rep. 1966, 50, 219. Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, 1970, 537. An effective amount of a compound of this invention can range from about 0.1 mg/kg to about 100 mg/kg. Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments such as the use of other anti- inflammatory agents.
The pharmaceutical composition may be administered via the parenteral route, including orally, topically, subcutaneously, intraperitoneally, intramuscularly, and intravenously. Examples of parenteral dosage forms include aqueous solutions, isotonic saline or 5% glucose of the active agent, or other well-known pharmaceutically acceptable excipient. Solubilizing agents such as cyclodextrins, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the therapeutic compounds . compound of this invention can be formulated into dosage forms for other routes of administration utilizing conventional methods. For example, it can be formulated in a capsule, a gel seal, or a tablet for oral administration. Capsules may contain any standard pharmaceutically acceptable materials such as gelatin or cellulose. Tablets may be formulated in accordance with conventional procedures by compressing mixtures of a compound of this invention with a solid carrier and a lubricant. Examples of solid carriers include starch and sugar bentonite. A compound of this invention can also be administered in a form of a hard shell tablet or a capsule containing a binder, e.g., lactose or mannitol, a conventional filler, and a tableting agent.
The biological activities of a compound of this invention can be evaluated by a number of cell -based assays. One of such assays can be conducted using mononuclear cells from human peripheral blood (PBMC) . Human Interferon gamma (IFN-γ) and lipopolysaccharide are added to the cell-containing solutions to induce IL-12 production. A solution containing a compound of this invention is added to each well. The level of inhibition of IL-12 production can be measured by determining the amount of P70 (i.e., IL-12) by using a sandwich ELISA assay -1 with anti-human IL-12 antibodies. ICso of each test compound can then be determined and potent compounds are selected for further testing.
The selected compounds can be further assayed in parallel on two types of cells, PBMC and human leukemia mononuclear cell line (THP-1) , for verification. More specifically, each test compound is added to a well of stimulated PBMC or THF-1 cells. PBMC are stimulated by a combination of IFN-γ and LPS, and THP-1 cells are stimulated by a combination of IFN-γ and pansorbin. The amount of P70 present in each well is then measured using a sandwich ELISA with anti -human IL-12 antibodies and IC is determined for each test compound.
The cytotoxity of the test compounds of this invention can be determined by using a bioreductive assay. Specifically, PBMC and THP-1 cells are incubated with the test compounds. Viability are evaluated by the ability of mitochondrial dehydrogenases of the incubated cells to reduce 3- (4, 5-dimethylthiazole-2-yl) -5- (3- carboxymethoxy-phenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS) in the presence of phenazine methosulfate (PMS) .
Compounds of this invention can also be evaluated by animal studies. One of such studies involves the ability of a test compound to inhibit septic shock. Animals are injected with LPS to induce septic shock. Mortality rate of the induced animals is monitored after administering to the animals a test compound and compared with that of a control experiment in which the induced animals are not treated. The following specific examples, which describe syntheses and biological testings of compounds of this invention, are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
In the following examples, XH nuclear magnetic resonance spectra were recorded on a Varian Mercury 300 MHz spectrometer. ES mass spectra were recorded on a Finnigan Navigator mass spectrometer.
Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific examples, which described syntheses, screening, and biological testing of various compounds of this invention, are therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications recited herein, including patents, are hereby incorporated by reference in their entirety.
Example 1
Preparation of compound 1
Step (1) :
Cyanuric chloride (18.7 g, 0.10 mol) was added to a solution of methylene chloride (100 mL) . Phenethyl alcohol (12.2 g, 0.10 mol) and N, N-dimethyacetamide (26.1 g, 0.30 mol) were then added after cyanuric chloride was dissolved. The reaction mixture was refluxed for 10 hours, cooled to room temperature, diluted with methylene chloride (100 ml), washed with water (100 ml, 3 times), dried over MgSO , and then filtered. Step (2) : Morpholine (8.70 g, 0.10 mol) and diisopropylethylamine (12.9 g, 0.10 mol) were dissolved in 20 ml methylene chloride and added dropwise into the filtrate from step (1) at 0°C. The reaction was monitored by TLC (EtOAc :Hexane, 1:4). After the product was formed, the reaction mixture was washed with IN HCI (50 ml, 3 times), saturated NaHCO. (50 ml), brine (50 ml), then dried over MgSO . The solvent was removed under reduced pressure. The crude residue was recrystallized from acetone/water solution to give 20.5 g of the desired triazine monochloride intermediate. Step (3)
The triazine monochloride intermediate (20.0 g, j0 0.062 mol) was dissolved in 100 ml ethanol and added dropwise to a solution of hydrazine monohydrate (25.0 g, 0.62 mol) in ethanol (50 ml) . The mixture was stirred at room temperature for 30 minutes before 20 ml water was added. Excess ethanol was then removed under reduced j pressure and the desired triazinyl hydrazine precipitated out which was collected by filtration and washed with water.
Triazinyl hydrazine (316 mg, 1.0 mmol) and indole 3- carboxylaldehyde (145 mg, 1.0 mmol) were added to 5 ml 0 methanol and warmed to form a homogeneous solution. Two drops of glacial acetic acid was then added. After the reaction mixture was allowed to stand at room temperature for 10 hours, the product precipitated which was then filtered, washed with methanol, and dried under reduced 5 pressure to yield compound 1 (395 mg, 89%) . λ NMR
(CD3COCD3) 8.34 (bd, 1, j=8.0), 8.28 (s, 1), 7.60 (s, 1), 7.39 (d, 1, =8.2), 7.34-7.69 (m, 7), 4.60 (t, 2, j
=7.4), 3.90-3.86 (m, 4), 3.79-3.75 (m, 4), 3.30 (t, 2, j=7.4); MS (ESI) : m/z 444 (M+H+) . 0
Example 2
Preparation of compound 2 Steps (1) and (2) of the preparation were prepared in an identical manner described in Example 1 except that 2- (4-methoxyphenyl) ethanol was used instead of phenethyl alcohol . 5 Step (3) :
Triazinyl monochloride (330 mg, 1.0 mmol) was added to 10 ml of 1,4 -dioxane, followed by the addition of 3- aminocarbazole (182 mg, 1.0 mmol) and diisopropylethylamine (129 mg, 1.0 mmol) . The reaction
JO mixture was heated to 100°C for 8 hours, cooled to room temperature, diluted with ethyl acetate (50 ml) , washed with water and brine, dried over MgSO , filtered, and concentrated under reduced pressure. The crude residue was purified by column chromatography (silica; j5 EtOAc/hexane : 3/7) to yield 270 mg of compound 2 (58% y -"ield). ESMS : calculated for C28H2BN6O3 : 496.5; found:
497.2 (M+H) . Ω NMR (DMSO) 2.92 (t, 2H, =6.7), 3.63-3.69 (m, 8H) , 3.71 (s, 3H) , 4.41 i t , 2H, j=7 . 2 ) , 6.82 (br, s, 2H) , 6.87 (d, IH, j=7.8), 7.08 (br, s, IH) , 7.17 (br, s, 0 2H) , 7.24 (d, IH, j=8.1), 7.31-7.45 (m, 5H) , 7.49 (br, s, IH) , 7.88 (br, s, IH) , 8.24 (s, IH) , 9.49 (s, IH) , 11.12 (s, IH) .
Example 3 Preparation of compound 3 Step (1) :
Cyanuric chloride (2 g, 10.8 mmol) and 4-hydroxy-3- methoxyphenethyl alcohol (1.6 g, 10.8 mmol) were dissolved in CH Cl (25 ml). N, N-dimethylacetamide (2.8 0 g, 32.5 mmol) was then added. The reaction mixture was refluxed for 3 hours, washed with water (3 times) , and then dried over MgSO . The dried solution was concentrated under reduced pressure to yield the desired triazine dichloride intermediate Step (2) :
The triazine dichloride intermediate (3.0 g, 10 5 mmol) was dissolved m acetone (30 ml) After the acetone solution was cooled to 0°C, a 10 ml aqueous solution of sodium bicarbonate (0.842 g, 10 mmol) was added to the acetone solution with stirring. Morpholine (0.87 ml, 10 mmol) was added dropwise to mixture and j0 white precipitate was formed within 10 minutes The precipitate was filtered and washed with water (3 times) and dried under vacuum to yield the desired triazine monochloride intermediate (4.0 g, >98%) as a white solid. Step (3) : j5 The triazine monochloride intermediate (3.5 g,
9.98 mmol) was dissolved m 20 ml of THF, followed by the addition of a solution of hydrazine (3.2 ml, 99 mmol) m ethanol (20 ml) The mixture was allowed to react until a white precipitate was formed (m about 10 minutes) . 0 The solid was filtered , washed 3 times with water, and dried under vacuum to afford 3.1 g of the tπazme hydrazine intermediate as a white solid.
The triazine hydrazine (0.50 g, 1.44 mmol) was dissolved m methanol (10 ml) and stirred at room 5 temperature. Indole-3 -carboxyaldehyde (0.21 g, 1.44 mmol) was added to the solution, followed by the addition of two drops of acetic acid. The reaction mixture was refluxed for 5 minutes, and the product precipitated upon cooling. The precipitate was filtered, washed 3 times 0 with water, and dried under vacuum to afford compound 3 (0.45 g, 66%) as a pale yellow solid XH NMR (CDC13) 3.02(t, 2H, j=7.2), 3.74 (m, 4H) , 3.82 (m, 4H) , 3.90 (s, -OCH3, 3H) , 4.13 (m, 2H) , 4.56 (t, 2H, j^=6.6), 6.71 (d, IH) , 6.83 (m, 2H) , 7.19 (m, 3H) , 7.38 (d, IH, =8.4), 7.52 (sharp d, IH, j=3.3), 8.38 (d, IH, j=7.2), 8.50 (s, IH) . ESMS calculated for C 25H27N7O4 : 489.53; found: 490.0
(M+H) .
5
Example 4
Preparation of compound 4
Step (1) :
Cyanuric chloride (13.66 g, 74 mmol) was dissolved j0 in methylene chloride (100 ml) at -78°C, followed by the addition of diisopropylethylamine (12.9 ml, 74 mmol).
The reaction mixture was stirred for 5 minutes.
Morpholine (6.46 ml, 74 mmol) was added dropwise into the reaction mixture in 10 minutes. The resulting white j precipitate was filtered, washed with water, and dried to afford the desired intermediate in quantitative yield (17 g, 100%) .
Step (2) :
2- (2 -Hydroxyethyl) pyridine (2 g, 16.2 mmol) was 0 dissolved in THF (20 ml) at 0°C. 6.5 ml of 2.5 M n-butyl lithium (16.2 mmol) was into the pyridine solution dropwise in 5 minutes. The resulting solution was then added dropwise via cannula to a triazine dichloride solution (3.8 g, 16.2 mmol, in THF) at -78°C. The 5 reaction was allowed to warm to room temperature for overnight to yield the triazine monochloride intermediate
(2.8 g, 54%) as a white powder.
Step (3) :
Hydrazine (0.5 ml, 15.5 mmol, 5 eq. ) was dissolved 0 in 10 ml ethanol at room temperature. The triazine monochloride intermediate (1 g, 3.11 mmol) was added to a solution of ethanol (20 ml) and heated to 60°C before adding into the hydrazine solution. After stirring for 30 minutes, white crystals precipitated, which were then filtered, washed with water and air dried to yield the triazine hydrazine intermediate (781 mg, 78%) as a white powder .
Indole-3 -aldehyde (1.05 g, 7.25 mmol) and the triazine hydrazine intermediate (2.3 g, 7.25 mmol) were added to 30 ml of methanol at room temperature. 5 ml of acetic acid was added to the reaction mixture and was refluxed for 5 minutes. Upon cooling, a white precipitate was formed, which was filtered and washed with water to yield compound 4 as a white powder (1.7 g, 52%). Η NMR (CDC1 3.28 (t, 2H, j=6 . 9 ) , 3.7 (broad s,
4H) , 3.86 (broad s, 4H) , 4.73 (broad t, 2H) , 7.14-7.24 (m, 2H) , 7.27-7.30 (m, 3H) , 7.37 (<j, IH, =8.1), 7.45 (d, IH, j=2 . 4 ) , 7.59 (t, IH, J-7.5), 8.14 (s, IH) , 8.42 ( d, IH, j=7.8), 8.49 (s, IH) , 8.56 { __ , IH, j=8.5). ESMS calculated for C 23H24N8O2 : 444.49; found: 445.2 (M+H) .
Example 5
Preparation of compound 5
Steps (1) and (2) of the preparation were prepared in an identical manner described in Example 3 except that (3 , 4-dimethoxyphenyl) ethanol was used instead of 4- hydroxy-3-methoxyphenethyl alcohol . Step (3) :
The triazine monochloride intermediate (760 mg, 2.0 mmol) was dissolved in 10 ml DMF. 4-(N-(2- methoxyphenyl) amino) aniline (429 mg, 2.0 mmol) and DIEA (387 mg, 3.0 mmol) were then added to the DMF solution. The reaction mixture was allowed to react at 100°C for 15 hours. After cooling to room temperature, the mixture was diluted with ethyl acetate (50 ml), washed with HO (3 X 25 ml) , brine (25 ml) , dried over MgSO , filtered, and concentrated under reduced pressure. The resulting crude residue was further purified by crystallization from acetone/water to give 970 mg of compound 5 (87%) . λΗ. NMR (CDC13) 7.36 (bd, 2, ,7=8.8), 7.02 (d, 2, j=8.8), 6.92-6.78 5 (m, 8), 5.44 (s, 1), 4.47 (t, 2, j=7.4), 3.86 (s, 3),
3.85 (s, 3), 3.84 (s, 3), 3.83-3.78 (m, 4), 3.74-3.69 (m, 4), 3.02 (t, 2, j=7.4); MS (ESI): m/z 559 (M+H+) .
Example 6 j0 Preparation of compound 6
Steps (1) and (2) of the preparation were identical to the corresponding steps described in Example 5. Step (3) :
Triazine monochloride intermediate (0.3 g) , 5- j thienyl-2 -aminothiophene (0.143 g) , anhydrous K2C03 (0.545 g) were added to 10 ml of DMSO. The reaction mixture was heated at 100-120°C and stirred for overnight. After cooling to room temperature, water was added and then extracted by CHC1 . The extract was dried over MgSO and 0 evaporated. Residue was purified by column chromatography with a mixture of hexane: ethyl acetate (1:1) as an eluent . Yield = 257 mg (62%). XH NMR (300 MHz, CDC13) , 7.61 (m, IH) ; 7.17-7.15 (m, IH) ; 7.10-6.92 (m, 2H) ; 6.91 (d, =3.9 Hz, IH) ; 6.86-6.76 (m, 3 H) ; 6.48 5 (d, -=3.9 Hz, IH) ; 4.50 (t, =7.2 Hz, 2H) ; 3.97-3.68 (m, 8H) ; 3.86 (s, 6H) ; 3.06 (t, j^7.2 Hz, 2H) ; MS m/z: 526 (M+H) .
Example 7
Preparation of Compound 7
Compound 7 was prepared in a similar manner as described in Examp ^le 2. ESMS : calculated for C30H31NSO4 :
5 526; found: 527.4 (M+H) . Η-NMR (DMSO) 2.93 (t, 2H, j==6.9) , 3.63-3.69 (m, 14H) , 4.44 (t, 2H, j=7.0) , 6.78 (br s, 2H) , 6.89 (s, IH) , 7.1 (br s, IH) , 7.33-7.44 (m, 5H) , 7.5 (m, IH) , 7.8-7.95 (br s, IH) , 8.45 (s, IH) , 9.49 (s, IH) , 11.1 (s, IH) .
Example 8
Preparation of Compound 8
Compound 8 was prepared in a similar manner as described in Examp cle 2. ESMS Calculated for C22H29N7O2 : j5 495.0; found: 496.2 (M+H). Η NMR (DMSO) 1.16 (t, 3H, -7.5), 2.58 (q, 2H, j=7.5), 3.12 (t, 2H, =7.0), 3.63-3.72 (m, 8H) , 4.62 (t, 2H, j=7.2), 7.08 (m, IH) , 7.24 (m, IH) , 7.31-7.44 (m, 5H) , 7.53 (m, IH) , 8.36 (s, IH) , 8.42 (s, IH) , 9.49 (s, IH) , 11.10 (s, IH) . 0
Example 9
Preparation of Compound 9
Compound 9 was prepared in a similar manner as described in Example 6. NMR (300 MHz, CDC13) 9.80 (s, 5 IH) ; 7.39-7.33 (m, 2H) ; 7.10-7.04 (m, 2H) ; 6.86-6.78 (m,
3H) ; 4.60-4.53 (m, 4H) ; 3.96-3.58 (m, 8H) ; 3.87 (s, 6H) ;
3.08 (t, J=7.5 Hz, 2H) ; 1.51 (t, J=7.2 Hz, 3 H) . MS m/z 582 (M+H)+:
Example 10
Preparation of Compound 10
Compound 10 was prepared in a similar manner as described in Example 2. Η NMR (300 MHz, CDC1 ) : δ 5 3.7-3.9 (m, 8H) , 4.25 (t, j=5.4 Hz, 2H) , 4.58(t, j=b.A
Hz, 2H) , 7.1 (brs, IH) , 7.19-7.23 (m, IH) , 7.36 (d, IH) ,
8.18 (s, IH) , 8.22 (brs, IH) . MS 525.2 (M+H).
]0 Example 11
Preparation of Compound 11
Compound 11 was prepared in a similar manner as described in Exam ■p^le 2. ESMS: calculated for C29H29N5O5 :
527.5; found: 528.2 (M+H). Η NMR (DMSO) 2.94 (t, 2H, j5 j=6.9), 3.64-3.70 (m, 14H) , 4.46 (t, 2H, j^=6.9), 6.79 (q, 2H, j=:6.9), 6.90 (s, IH) , 7.33 (m, IH) , 7.49 (t, IH, j=8.4), 7.61 (m, 2H) , 7.85 (br s, IH) , 8.49 (s, IH) , 9.70 (s, IH) .
0 Example 12
Preparation of Compound 12
Compound 12 was prepared in a similar manner as described in Examp ^le 3. ESMS: calculated for C25H27N7O3 :
503; found: 504.2 (M+H) . XH NMR (DMSO) 2.95 (br s, 2H) , 5 3.63-3.72 (m, 14H) , 3.85 (br s, IH) , 4.41-4.52 (m, 2H) , 6.79-6.91 (m, 4H) , 7.13 (br s, 2H) , 7.37 (d, IH, j=S .1) , 7.68 (d, IH, j==2.4) , 8.27 (s, IH) , 8.36 (br s, IH) , 10.88 (s, IH) , 11.40 (s, IH) .
Example 13
Preparation of Compound 13
Compound 13 was prepared in a similar manner as described in Example 3. m NMR (DMSO-d : δ l-°5 (m, 2H) , 3.24 (m, 2H) , 3.6-3.8 (m, 8H) , 4.0-4.1 (m, 4H) , 6.88 (s, IH) , 6.97 (brs, IH) , 7.07 (t, =7.2 Hz, IH) , 7.15 (d, IH) , 7.19 (m, IH) , 7.39 (d, IH) , 7.64 (s, 2H) , 8.35 (m, IH) , 8.44 (m, IH) , 11.36 (s, IH) . MS m/e 447 (M+H) . 0
Example 14
Preparation of Compound 14
Compound 14 was prepared in a similar manner as described in Examp cle 2. ESMS Calculated for C28H27N4O6 :
15 515.5; found: 515.2 (M+H) . Η-NMR (CDC1.) 1.85 (m, 4H) ,
2.62 (t, 2H) , 2.71 (t, 2H) , 2.93 (t, 2H, j==7.8) , 3.66 (m,
8H) , 3.78 (s, 3H) , 3.82 (s, 3H) , 4.40 (t, 2H, j==7.2) ,
6.60-6.71 (m, 3H) , 6.86 (dd, IH, j=2.7) , 7.18-7.21 (m,
2H) , 7.69 (s, IH) . 0
Example 15
Preparation of Compound 15
Compound 15 was prepared in a similar manner as described in Example 1. NMR (CDC1.) 8.48-8.35 (m, 3H) , 5 8.04 (s, IH) , 7.66 (s, IH) , 7.44-7.25 (m, 8H) , 4.58 (t, 2H, j=l .6) , 3.90-3.86 (m, 4H) , 3.82-3.78 (m, 4H) , 3.13 (t, 2H, j=7.6), 2.67 (s, 3H) ; MS (ESI) : m/z 486 (M+H).
Example 16 0 Preparation of Compound 16
Compound 16 was prepared in a similar manner as described in Examp cle 4. ESMS : calculated for C22H29N702 :
495.0; found: 496.2 (M+H). *H NMR (DMSO) 1.16 (t, 3H, j-=7.5), 2.58 (q, 2H, j=7 . 5 ) , 3.12 (t, 2H, j=7.0), 3.63-3.72 (m, 8H) , 4.62 (t, 2H, =7.2), 7.08 (m, IH) , 7.24 (m, IH) , 7.31-7.44 (m, 5H) , 7.53 (m, IH) , 8.36 (s, IH) , 8.42 (s, IH) , 9.49 (s, IH) , 11.10 (s, IH) .
Example 17
Preparation of Compound 17
Compound 17 was prepared in a similar manner as described in Example 6. Η NMR (300 MHz, DMSO-dg) 7.45 (s, IH) ; 6.83-6.75 (m, 3H) ; 6.60 (br s, IH) ; 6.54 (m, 2H) ; 5.95 (s, IH) ; 4.52 (t, =7.2 Hz, 2 H) ; 3.90-3.67 (m, 8H) ; 3.89,3.87 (2s, 6H) ; 3.00 (t, j=7.2 Hz, 2H) ; MS m/z: 494 (M+H) .
Example 18
Preparation of Compound 18
Compound 18 was prepared in a similar manner as described in Example 6. XH NMR (300 MHz, CDC13) , ppm: 7.75 (s, IH) ; 6.80-6.70 (m, 3H) ; 5.26 (br.S. IH) ; 4.50 ( ' J=7 - 1 Hz' 2H> '" 4-36 (<3' "=7-° Hz, 2H) ; 3.83, 3.81
(2s, 6H) ; 3.71-3.60 (m, 8H) ; 3.98 (t, =7.1 Hz, 2H) ; 1.24 (t, j=7.0 Hz, 3H) ; MS m/z: 582 (M+Na) .
Example 19 Preparation of Compound 19
Compound 19 was prepared in a similar manner as described in Example 6. XH NMR (CDC1.) 8.74-8.66 (m, IH) , 8.11 (s, IH) , 7.38-7.24 (m, 9H) , 4.63 (t, 2H, J=l . 1 ) ,
3.90-3.86 (m, 4H) , 3.81 (s, 3H) , 3.81-3.77 (m, 4H) , 3.65 (s, 3H) , 3.17 (t, 2H, j=l .7) ; MS (ESI): m/z 472 (M+H).
Example 20
Preparation of Compound 20 Compound 20 was prepared in a similar manner as described in Example 1. *H NMR (CDC13) 10.1 (s, IH) , 9.27 (bs, IH) , 8.19 (s, IH) , 7.94 (s, IH) , 7.40-7.21 (m, 7H) , 6.89-6.85 (m, IH) , 4.52 (t, 2H, j=7.4), 3.89-3.85 (m,
4H) , 3.73 (s, 3H) , 3.81-3.77 (m, 4H) , 3.09 (t, 2H, j-=7.4); MS (ESI) : m/z 474 (M+H).
Example 21
Preparation of Compound 21
Compound 21 was prepared in a similar manner as described in Examp cle 6. ESMS Calculated for C28H27N4O6 :
515.5; found: 515.2 (M+H) . Η-NMR (CDC13) 1.85 (m, 4H) ,
2.62 (t, 2H) , 2.71 (t, 2H) , 2.93 (t, 2H, j==7.8) , 3.66 (m,
8H) , 3.78 (s, 3H) , 3.82 (s, 3H) , 4.40 (t, 2H, j=7.2) ,
6.60-6.71 (m, 3H) , 6.86 (dd, IH, j=2.7) , 7.18-7.21 (m,
2H) , 7.69 (s, IH) .
Example 22
Preparation of Compound 22
Compound 22 was prepared in a similar manner as described in Examprle 6. ESMS Calculated for C27H32N6O4 :
504.5; found: 505.2 (M+H). Η NMR (DMSO) 2.05 (br s, 3H) , 2.26 (s, 3H) , 2.91 (t, 2H, ==7.2), 3.61-3.70 (m, 14H) , 4.41 (t, 2H, j=7.2) , 6.67-6.9 (m, 4H) , 7.08 (s, 2H) , 7.76 (m, IH) , 9.26 (s, IH) , 10.49 (s, IH) .
Example 23
Preparation of Compound 23
Compound 23 was prepared in a similar manner as described in Example 6. NMR (CDC1.) 7.95 (s, IH) ,
7.85-7.20 (series of m, 11H) , 7.08 (bs, IH) , 4.53 (t, 2H, j==7.4), 3.85-3.81 (m, 4H) , 3.79-3.75 (m, 4H) , 3.11 (t, 2H, j=7.4); MS (ESI) : m/z 480 (M+H). Example 24
Preparation of Compound 24
Compound 24 was prepared in a similar manner as described in Examp rle 6. ESMS Calculated for C27H31NS04S :
521.6; found: 522.2 (M+H). Η NMR (DMSO) 2.42 (s, 2H) , 2.93 (t, 2H, j=7 . 2 ) , 3.64-3.71 (m, 14H) , 4.44 (t, 2H, r=7.5), 6.75 (d, IH, =9.3), 6.84 (d, IH, j=8.4), 6.88 (s, IH) , 7.38 (d, IH, J=8.7), 7.68 (d, IH, j==8.7), 8.21 (s, IH) , 9.63 (s, IH) .
Example 25
Preparation of Compound 25
Compound 25 was prepared in a similar manner as j5 described in Example 6. *H NMR (300 MHz, DMSO 5 - 6 )
10.50, 9.80 (2 br s, IH) 7.43 (s, IH) ; 7.59-7.29 (m, 2H) ; 7.18-7.02 (m, IH) ; 6.96-6.73 (m, 3H) ; 6.30 (br S, IH) ; 4.43 (t, j=7.2 Hz, 2H) ; 3.78-3.58 (m, 8H) ; 3.71 (s, 6H) ; 2.94 (t, =7.2 HZ); MS m/z: 510 [M+H] . 0
Example 26
Preparation of Compound 26
Compound 26 was prepared in a similar manner as described in Example 5. W NMR (CD30D) 8.17 (ddd, IH, 5 J=8.5, 1.7, 1.7), 7.92 (ddd, 2H, j =6.9, 1.7, 1.7),
7.76-7.46 (m, 9H) , 7.33-7.18 (m, 2H) , 4.55 (t, 2H, =7.2), 3.85-3.81 (m, 4H) , 3.78-3.74 (m, 4H) , 3.08 (t,
2H, =7.2); MS (ESI): m/z 497 (M+H).
0 Example 27
Preparation of Compound 27
Compound 27 was prepared in a similar manner as described in Example 5. XH NMR (CDC1 ) 7.36 (bd, 2H, j-=8.8), 7.35-7.22 (m, 5H) , 7.03 (ddd, 2H, j=9 . 0 , 2,2), 6.90 (ddd, 2H, j-=8.8,2,2), 6.85 (ddd, 2H, j=9.0, 2, 2), 6.75 (bs, IH) , 5.43 (s, IH) , 4.50 (t, 2H, j=7 . 7 ) ,
3.84-3.79 (m, 4H) , 3.80 (s, 3H) , 3.75-3.70 (m, 4H) , 3.09 5 (t, 2H, j=7.7); MS (ESI) : m/z 499 (M+H).
Example 28
Preparation of Compound 28
Compound 28 was prepared in a similar manner as 10 described in Example 6. NMR (300 MHz, CDC13) , ppm:
8.37-8.24 (m, IH) ; 8.10-7.95 (m, 2H) ; 6.88-6.67 (m, 4H) ; 6.61 (br s, IH) ; 4.51 (t, j=6 .9 Hz, 2H) ; 3.90-3.66 (m, 8H) ; 3.86 (s, 6H) ; 3.02 (t, J=6.9 Hz, 2H) ; MS m/ Z : 544
(M+H) .
15
Example 29
Mononuclear cells from human peripheral blood (PBMC) were harvested from a leukopak using standard procedures and diluted to three million per ml with RPMI . Also
20 present in the RPMI solution were fetal calf serum (10%) , penicillin, streptomycin and L-glutamate. Human Interferon gamma (IFN-γ) was added to the solution containing the cells at the concentration of 60 units/ml (obtained from Boehringer Mannheim; catalog no. 1040596) .
25 100 μl of this solution was then added to each well in a 96 well plate with U-shaped bottoms. The plate was then incubated overnight under a 7% CO atmosphere at 37°C. A RPMI stock solution (4X) was prepared for each test compound of this invention. Each test compound was added
30 to a well of the 96 well plate with a final concentration of 1 μg/ml, followed by the addition of a RPMI stock solution (4X concentration) containing lipopolysaccharide (LPS; obtained from Serratia Marscencens Sigma; catalog no. L-4766) with a final concentration of 1 μg/ml . The plate was gently vortexed and incubated for 16 hours under a 7% C02 atmosphere at 37°C. After harvesting the supernatant from each well, the amount of P70 in the supernatant was measured using a sandwich ELISA with anti-human IL-12 antibodies (obtained from R&D systems; catalog no. mAb 611 and catalog no. BAF219) . A number of the test compounds of this invention demonstrated a level of above 70% in inhibiting IL-12 production when compared to the data obtained from a control experiment in which no compound was added. Nine compounds were selected for further testing described in the following example.
Example 30
The specificity of the nine selected compound (see Example 29) was tested on PBMC and human leukemia mononuclear cell line THP-1 in parallel to verify results .
PBMC were plated in wells of a 96-well plate at a concentration of 500,000 cells per well and stimulated by adding IFN-γ (200 U/mL) and LPS (1 μg/mL) . THP-1 cells were plated in wells of a 96-well plate at a concentration of 800,000 cells per well (100 μl). Human IFN-γ was added at 2000 U/ml . The plate was incubated overnight under a 7% CO atmosphere at 37°C. Each selected test compound (in 4X RPMI solution) was then added to a well of the 96 well plate with a final concentration of 1 μg/ml, which was then followed by the addition of Staph Aureus Cowan I (SAC or Pansorbin; obtained from Calbiochem; Lot # B15921) with a final concentration of 0.05%. The plate was then gently vortexed and incubated for 16 hours under a 7% CO 2 atmosphere at 37°C. Supernatant was harvested and was assayed for the amount of P70 present by using a sandwich ELISA with anti -human IL-12 antibodies (obtained from R&D systems; catalog no. mAb 611 and catalog no. BAF219) .
The nine selected test compounds all showed similar biological activities towards both PBMC and THP-1 cells. Among these selected compounds, one showed an IC of about 30 nM for the PBMC cell line and an IC 50 of about
200 nM for the THP-1 cell line; six showed an IC 50 of between 1-3 nM for the PBMC cell line and an IC 50 of between 8-20 nM for the THP-1 cell line; and two compounds unexpectedly showed an IC of about 0.1 nM for the PBMC cell line and an IC 50 of about 0.8 nM for the
THP-1 cell line. The two most potent compounds showed a 10-fold increase in inhibiting IL-12 production over a known anti-inflammatory compound, dexamethazone .
Example 31
The nine selected compounds (see Example 29) were also assayed for cytotoxicity using a Cell Titer 96 Aqueous Non-radioactive kit (obtained from Promega, order 5 no. G5421) . Phenazine methosulfate (obtained from Sigma; catalog no. P 5812) was added as an electron donor to wells containing PBMC (500,000 cells per well) and test compounds (final concentration of test compounds = 1 μg/ml) . 3- (4, 5-Dimethylthiazole-2-yl) -5- (3- j0 carboxymethoxy-phenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS) was then added. Cells were incubated for 2 hours under a 7% CO atmosphere at 37°C. Supernatant was harvested and its absorbance at 490 nm was recorded. Cell viability data was obtained from the level of j5 bioreduction of MTS by mitochondrial dehydrogenases . The data was then compared to that obtained from a control experiment in which no test compound was added to the cells. The cytotoxicity assay was also carried out with THP-1 cells. A test compound is considered cytotoxic if 0 the absorbance is under 70% of that of the control.
The nine test compounds all showed similar trend in cytotoxity toward the two cell lines. For the PBMC cell line, one compound showed a CC of under 1 μM; five compounds showed a CC of between 2-10 μM; and three 5 compounds showed a CCso of 20 μM or above. For the THP-1 cell line, one compound showed a CC of about 2 μM; five compounds showed a CC of about 20 μM; and three compounds showed a CC of above 20 μM. Compared with an assay in which dexamethazone was added, four compounds 0 showed a lower cytotoxity toward the PBMC cell line, and three compounds showed a lower cytotoxity toward the THP- 1 cell line. Example 32
Three compounds of this invention were tested an animal study using Balb/c mice. The mice were divided into groups of five. Septic shock was induced m each of them by single tradermal injection of LPS (1 μg/mL) m the foot pad. After 24 hours, a group of mice received (1) no treatment; another group received (2) vehicle only (10% DMSO and 18% Cremophor RH40) ; or three groups received (3) test compounds. More specifically, each group received a different test compound at a dosage of 10-20 mg/kg. The mice were dosed daily for three days and the mortality rate m each group was then recorded. The mice all died m the groups that received no treatment or vehicle only. Among the groups that received test compounds, two had a survival rate of 60% and 80%.
Other Embodiments From the above description, one skilled m the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.
What is claimed is:

Claims

1. A compound of the following formula:
^IΛ ^L2
W
'X
wherein
X is triazinyl;
L1 is -A^B1-, in which -A1- is -(CH(Ra)) -, -0-, -S-, or -N(Rb)- and -B1- is -(CH(Rc))n- or a bond, each of Ra and Rc, independently, being hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; R being hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; and each of m and n, independently, being 1-8;
W is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy;
L2 is -A2-B2-, in which A2 is a bond, -N(R1)-, or - (-C(R2) (R3) -) -, and B2 is a bond, -N=C(R4)-, -C(R5)=N-,
-C(R6)=C(R7) -, -N(R8)=N(R9) -, -N (R10) -C (R11) (R12) - , -0-C(R13) (R14) -, -CO-C(R15) (R16) -, -CO-N(R17)-, -N(R18)-CO-, -CO-, -CO-0-, -CO-S-, -S-C(R19) (R20) -, -CS-C (R21) (R22) - , -CS-
N(R23)-, -N(R24)-CS-, -CS-, -S02-, provided that -A2-B2- cannot be a bond; or -A2-B2- is -O- , -S-, - ( -0- (CH2) q-0- ) r-
, - (-N(R25)-(CH2)s-CO-)t-, or - ( -N (R26) - (CH2) U-N (R27) - ) v- , each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 , R13 , R14, R15, R16, R17, R18, R19, R20, R21, R22 , R23 , R24 , R25 , R26, and R27, independently, being hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl; and each of p, q, r, s, t, u, and v, independently, being 1, 2, or 3;
Y is -R'-L'-R" wherein R' is a bond, or cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, or alkoxycarbonylimino; L1 is a bond, - 0-, -S-, -N(R28)-, -N(R29)-CO-, -CO-N(R30)-, -C0-0-, or -0-CO-, each of R28, R29, and R30, independently, being hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl; and R" is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy; and
Z is morpholinyl optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy; or a salt thereof.
2. The compound of claim 1, wherein R" is a tricyclic fused aryl or heteroaryl .
3. The compound of claim 2, wherein R" is a tricyclic fused aryl or heteroaryl.
4. The compound of claim 4, wherein A2 is -N(RX) and B2 is a bond.
The compound of claim 4, wherein -A^B1- is -O- or
- (CH(Ra) ) m- in which Ra is hydrogen and m is 1-3, and W is aryl or heteroaryl, optionally substituted with alkyl, alkoxy, hydroxyl, or halo.
The compound of claim 5, where the compound is
7. The compound of claim 2, wherein A2 is -N(R1)- and B2 is a bond, or -A2-B2- is -O- .
8. The compound of claim 7, wherein A2 is -N CR1) - and B2 is a bond, R1 being hydrogen or alkyl.
9. The compound of claim 8, wherein R" is aryl or heteroaryl .
10. The compound of claim 9, wherein L1 is -0-, -N(R28)-, or -N(R29)-CO-, each of R28 and R29, independently, being hydrogen or alkyl .
11. The compound of claim 10, wherein -A^B1- is -O- or - (CH(Ra) ) m- in which Ra is hydrogen and m is 1-3, and W is aryl or heteroaryl, optionally substituted with alkyl, alkoxy, hydroxyl, or halo.
12. The compound of claim 11, where the compound is
13. The compound of claim 7, wherein -A2-B2- is -O- .
14. The compound of claim 13, wherein R" is aryl or heteroaryl .
15. The compound of claim 14, wherein L ' is -0-, -N(R28)-, or -N(R29)-CO-, each of R28 and R29, independently, being hydrogen or alkyl.
16. The compound of claim 15, wherein -A^B1- is -0- or - (CH(Ra) ) m- in which Ra is hydrogen and m is 1-3, and W is aryl or heteroaryl, optionally substituted with alkyl, alkoxy, hydroxyl, or halo.
17. The compound of claim 16, where the compound is 20.
18. The compound of claim 2, wherein A2 is -N(RX)- and B2 is -N=C(R4)-, -C(R5)=N-, -C (R6) =C (R7) - , or - N(R8)=N(R9) - .
19. The compound of claim 18, wherein A2 is -N(RX)- and B2 is -N=C(R4)-, each of R1 and R4, independently, being hydrogen or alkyl .
20. The compound of claim 19, wherein R" is aryl or heteroaryl .
21. The compound of claim 20, wherein -A^B1- is -O- or - (CH(Ra) ) m- in which R is hydrogen and m is 1-3, and is aryl or heteroaryl, optionally substituted with alkyl, alkoxy, hydroxyl, or halo.
22. The compound of claim 21, where the compound is
23. The compound of claim 18, wherein A2 is -N(R1)- and B2 is -C (R6) =C (R7) - , each of R1, R6, and R7, independently, being hydrogen or alkyl.
24. The compound of claim 23, wherein R" is aryl or heteroaryl .
25. The compound of claim 24, wherein -A^B1- is -O- or - (CH(Ra) ) m- in which Ra is hydrogen and m is 1-3, and W is aryl or heteroaryl, optionally substituted with alkyl, alkoxy, hydroxyl, or halo.
26. The compound of claim 25, where the compound is
27. A method of inhibiting IL-12 production, comprising administering to a patient in need thereof an effective amount of a compound of the following formula:
wherein
X is triazinyl;
L1 is -Ai-B1-, in which -A1- is -(CH(Ra)) -, -O- , -S- or -N(Rb)- and -B1- is -(CH(Rc))n- or a bond, each of Ra and Rc, independently, being hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; Rb is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; and each of m and n, independently, is 1-8; is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl, optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy;
L2 is -A2-B2-, in which A2 is a bond, -N(RX)-, or - (-C(R2) (R3) -)p-, and B2 is a bond, -N=C(R4)-, -C(R5)=N-,
-C(R6)=C(R7) -, -N(R8)=N(R9) -, -N (R10) -C (R11) (R12) - ,
-0-C(R13) (R14) -, -CO-C(R15) (R16) -, -CO-N(R17)-, -N(R18)-CO-,
-CO-, -CO-0-, -CO-S-, -S-C(R19) (R20) -, -CS-C (R21) (R22) - ,
-CS-N(R23)-, -N(R24)-CS-, -CS-, -S02-, provided that -A2-B2- cannot be a bond; or -A2-B2- is -0- , -S-, - ( -0- (CH2) q-0- ) r-
, - (-N(R25)- (CH2)s-C0-)c-, or - ( -N (R26) - (CH2) U-N (R27) - ) v- , each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 , R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, and R27, independently, being hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl; and each of p, q, r, s, t, u, and v, independently, being 1, 2, or 3;
Y is -R'-L'-R" wherein R' is a bond, or cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, or alkoxycarbonylimino; L1 is a bond, - 0-, -S-, -N(R28)-, -N(R29)-CO-, -CO-N(R30)-, -CO-O- , or -0-CO-, each of R28, R29, and R30, independently, being hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl; and R" is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy; and
Z is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy; or a salt thereof.
28. The method of claim 27, wherein Z is heterocycloalkyl .
29. The method of claim 28, wherein Z is morpholinyl .
30. The method of claim 29, wherein W is cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl.
31. The method of claim 30, wherein W is aryl or heteroaryl, optionally substituted with alkyl, alkoxy, hydroxyl, or halo.
32. The method of claim 29, wherein R" is a tricyclic fused aryl or heteroaryl.
33. The method of claim 32, wherein W is aryl or heteroaryl, optionally substituted with alkyl, alkoxy, hydroxyl, or halo.
34. The method of claim 29, wherein A2 is -N(RX)- and B2 is -N=C(R4)-, -C(R5)=N-, -C (R6) =C (R7) - , or
-N(R8)=N(R9) - .
35. The method of claim 34, wherein W is aryl or heteroaryl, optionally substituted with alkyl, alkoxy, hydroxyl, or halo.
EP00941360A 1999-06-17 2000-06-12 Inhibitors of il-12 production Withdrawn EP1185528A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13962399P 1999-06-17 1999-06-17
US139623P 1999-06-17
PCT/US2000/016094 WO2000078757A1 (en) 1999-06-17 2000-06-12 Inhibitors of il-12 production

Publications (2)

Publication Number Publication Date
EP1185528A1 EP1185528A1 (en) 2002-03-13
EP1185528A4 true EP1185528A4 (en) 2003-03-26

Family

ID=22487544

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00941360A Withdrawn EP1185528A4 (en) 1999-06-17 2000-06-12 Inhibitors of il-12 production

Country Status (5)

Country Link
EP (1) EP1185528A4 (en)
JP (1) JP2003502424A (en)
AU (1) AU781849C (en)
TW (1) TWI265929B (en)
WO (1) WO2000078757A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4105949B2 (en) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6653301B2 (en) * 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6462078B1 (en) * 2001-01-29 2002-10-08 Shionogi Bioresearch Corp. Epoxyvibsanin B
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
ZA200501124B (en) 2002-08-02 2006-10-25 Vertex Pharma Pyrazole compositions useful as inhibitors of GSK-3
CA2502356A1 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
AU2004251641A1 (en) * 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
EP1689403A4 (en) * 2003-11-10 2007-09-05 Synta Pharmaceuticals Corp Heteroaryl-hydrazone compounds
US7338951B2 (en) 2003-11-10 2008-03-04 Synta Pharmaceuticals Corp. Pyridine compounds
CA2545340A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
EP1737845A4 (en) * 2004-04-13 2010-07-21 Synta Pharmaceuticals Corp Disalt inhibitors of il-12 production
JP4990766B2 (en) * 2004-07-01 2012-08-01 シンタ ファーマシューティカルズ コーポレーション Disubstituted heteroaryl compounds
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
CA2586870A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
WO2006053112A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Process for preparing trisubstituted pyrimidine compounds
AU2005310143A1 (en) 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
EP1948193B1 (en) 2005-11-03 2015-01-07 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN101790532B (en) 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
EP2481730B1 (en) 2007-10-09 2013-12-18 Dow AgroSciences LLC Insecticidal (1,3,5)-triazinyl phenyl hydrazones
PT2254869T (en) 2008-03-07 2017-07-18 Acraf Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 and p40
MX2010009625A (en) 2008-03-07 2010-09-28 Acraf 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40.
AU2010259009A1 (en) * 2009-06-08 2012-01-12 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
EP2440055B1 (en) * 2009-06-09 2015-03-11 California Capital Equity, LLC Styryl-triazine derivatives and their therapeutical applications
WO2010144550A1 (en) * 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
US9321735B2 (en) 2010-07-20 2016-04-26 Vestaron Corporation Insecticidal triazines and pyrimidines
KR20200138714A (en) 2018-02-21 2020-12-10 에이아이 테라퓨틱스, 인코포레이티드 Combination therapy with apilimod and glutamate agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356412A1 (en) * 1988-08-16 1990-02-28 U C B, S.A. Use of 2-amino-4-morpholino-6-propyl-1,3,5-triazines in the preparation of a medicament for the treatment of cognitive and mental disorders
EP0527117A1 (en) * 1991-07-25 1993-02-10 U C B, S.A. Substituted cyclopropylamino-1,3,5-triazines
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1999032121A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1231369B (en) * 1964-03-05 1966-12-29 Basf Ag Process for the production of anthraquinone dyes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356412A1 (en) * 1988-08-16 1990-02-28 U C B, S.A. Use of 2-amino-4-morpholino-6-propyl-1,3,5-triazines in the preparation of a medicament for the treatment of cognitive and mental disorders
EP0527117A1 (en) * 1991-07-25 1993-02-10 U C B, S.A. Substituted cyclopropylamino-1,3,5-triazines
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5663334A (en) * 1993-07-16 1997-09-02 Smithkline Beecham Corporation Process for preparing pyrimidyl imidazoles
WO1999032121A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0078757A1 *

Also Published As

Publication number Publication date
AU781849B2 (en) 2005-06-16
JP2003502424A (en) 2003-01-21
WO2000078757A1 (en) 2000-12-28
AU781849C (en) 2006-03-02
EP1185528A1 (en) 2002-03-13
AU5607400A (en) 2001-01-09
TWI265929B (en) 2006-11-11

Similar Documents

Publication Publication Date Title
AU781849C (en) Inhibitors of IL-12 production
US6384032B1 (en) Inhibitors of IL-12 production
ES2244733T3 (en) DERIVATIVES OF N-ADAMANTILALQUIL-BENZAMIDA AS ANTAGONISTS OF THE P2X7 RECEIVER.
EP0747368B1 (en) Derivatives of monocyclic polyamines, their preparation, and their use as antiviral agents
ES2358988T3 (en) BENZAMIDE AND HETEROARILAMIDE AS ANTAGONISTS OF THE P2X7 RECEIVER.
ES2286634T3 (en) AZAINDOL COMPOUNDS AS QUINASE INHIBITORS.
CA2575232C (en) 5-substituted-2-phenylamino-benzamide as mek inhibitor
HU211237A9 (en) Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
EP2281818A1 (en) Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
JPH07504654A (en) Amine derivatives of oxo- and hydroxy-substituted hydrocarbons
KR20050098848A (en) 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as p2x7-inhibiors for the treatment of inflammatory diseases
EP3004059B1 (en) Dihydropyridinone mgat2 inhibitors
KR20170033339A (en) Indolizine derivatives which are applicable to neurodegenerative diseases
JPS63239281A (en) Imidazolidinone derivatives
EP2844643B1 (en) Pyrimidinedione carboxamide inhibitors of endothelial lipase
JP2018538355A (en) Benzamide derivatives
CA3081564A1 (en) Double-headed protease inhibitor
KR20200057662A (en) The derivative compounds of Azilsartan, intermediates thereof, preparation thereof and pharmaceutical composition comprising the same
JPWO2019235553A1 (en) Azetidine derivatives and their prodrugs
WO1998058930A1 (en) Triazolo-1,4-diazepine compounds and medicinal composition containing the same
EP0353474B1 (en) Glycerin derivative and its pharmacological use
EP2895483A1 (en) Ketone linked benzothiazole inhibitors of endothelial lipase
US6344456B1 (en) Piperazinone derivatives and their uses
JPS6310924B2 (en)
CA2337880A1 (en) Substituted piperazinones and therapeutic uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GILLIES, STEPHEN

Inventor name: VO, NHA HUU

Inventor name: ZHOU, DAN

Inventor name: WRONA, WOJCIECH

Inventor name: WARCHOL, TADEUSZ

Inventor name: BRUNKHORST, BEATRICE

Inventor name: WADA, YUMIKO

Inventor name: ONO, MITSUNORI

A4 Supplementary search report drawn up and despatched

Effective date: 20030206

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 29/00 B

Ipc: 7A 61K 31/5375 B

Ipc: 7C 07D 413/14 A

17Q First examination report despatched

Effective date: 20030627

RBV Designated contracting states (corrected)

Designated state(s): DE FR GB IT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080202